In cancer vaccination, the use of the Toll-like receptor 3 (TLR3) agonist polyinosinic-polycytidylic acid (poly(I:C)) as an adjuvant has been shown to increase the number of CTLs targeting tumor antigens.17 Here, TLR3 is linked to neoplasm.